Cocrystal Pharma to Present at Therapeutic Area Partnerships Conference, Boston, November 18-20
CC-31244 (HCV Non-Nucleoside Polymerase Inhibitor - NNI) Nominated for Infectious Diseases Top Projects to Watch
BOTHELL, WA and ATLANTA, GA -- (Marketwired) -- 11/18/15 -- Cocrystal Pharma, Inc. (OTCQB: COCP),a company focused on developing novel antiviral therapeutics for human diseases, today announced the company's drug candidate CC-31244 has been nominated as one of the top projects in infectious diseases to watch at the 10th Annual Therapeutic Area Partnerships meeting, hosted by IIR USA in Boston on November 18-20, 2015. As part of this recognition, Jeffrey Meckler, Cocrystal Chief Executive Officer, will present a company overview on Thursday, November 19. The following is a forward-looking statement within the meaning of section 27A(c)(1)(A)(i) and contains opinions regarding the importance of certain therapeutic areas that could differ materially from actual results.
CC-31244, a pan-genotypic Non Nucleoside Inhibitor, is highly potent and active against all genotypes (1-6) with no cytotoxicity in various cell systems. Currently, regulatory-filing enabling studies are in progress with a Phase 1 study anticipated in 2016. The preclinical safety profile and antiviral activity of this potential best-in-class pan-genotypic HCV NNI suggests that this compound may be an important component of all-oral, short duration HCV regimens.
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."
Top projects will be presented across today's "hottest" therapeutic areas including cardiovascular/metabolic diseases, neuroscience, anti-inflammatory/autoimmune diseases, oncology/immune-oncology, infectious and emerging diseases, advanced therapies; cell, gene & stem therapies, orphan and rare diseases and academic technology transfer. Each project has been hand-selected by an elite panel to ensure a high-quality slate of presenters. Details on the top projects to watch under each therapeutic area can be found at: http://www.iirusa.com/therapeuticareapartnership/agenda.xml
About Cocrystal Pharma, Inc.
Cocrystal is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. The company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. Cocrystal has previously received strategic investments from Teva Pharmaceuticals, OPKO Health (OPK), Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group. For further information about Cocrystal, please refer to www.cocrystalpharma.com.
Contact:
MDM Worldwide
David Zazoff
212-643-0417
Source: Cocrystal Pharma, Inc.
Released November 18, 2015